Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Elanco Animal Health

Healthcare US ELAN

23.67USD
-0.27(1.13%)

Last update at 2026-03-10T20:00:00Z

Day Range

23.6624.48
LowHigh

52 Week Range

8.0218.80
LowHigh

Fundamentals

  • Previous Close 23.94
  • Market Cap6416.67M
  • Volume3982667
  • P/E Ratio17.23
  • Dividend Yield-%
  • EBITDA862.00M
  • Revenue TTM4427.00M
  • Revenue Per Share TTM8.95
  • Gross Profit TTM 2430.00M
  • Diluted EPS TTM0.75

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -66.00000M -567.00000M -672.00000M 78.20M 114.10M
Minority interest - - - - -
Net income -74.00000M -472.00000M -560.10000M 67.90M 86.50M
Selling general administrative 1266.00M 1404.00M 996.60M 760.20M 735.20M
Selling and marketing expenses - - 996.00M - -
Gross profit 2505.00M 2631.00M 1606.70M 1600.70M 1493.00M
Reconciled depreciation 528.00M 556.00M 516.90M 314.50M 296.00M
Ebit 358.00M 297.00M 101.50M 342.60M 442.60M
Ebitda 886.00M 853.00M 461.40M 543.00M 640.00M
Depreciation and amortization 528.00M 556.00M 359.90M 200.40M 197.40M
Non operating income net other -32.00000M -5.00000M 178.30M -27.40000M -41.30000M
Operating income 358.00M 297.00M 101.50M 342.60M 313.80M
Other operating expenses 4028.00M 4463.00M 3350.10M 2701.00M 2753.00M
Interest expense 241.00M 236.00M 149.80M 78.90M 29.60M
Tax provision 8.00M -95.00000M -111.90000M 10.30M 27.60M
Interest income - - - 78.90M 29.60M
Net interest income -241.00000M -236.00000M -149.80000M -78.90000M -29.60000M
Extraordinary items - - - - -
Non recurring 183.00M 628.00M 623.70M 185.50M 128.80M
Other items - - - - -
Income tax expense 8.00M -95.00000M -111.90000M 10.30M 27.60M
Total revenue 4418.00M 4765.00M 3273.30M 3071.00M 3066.80M
Total operating expenses 2115.00M 2329.00M 1683.50M 1230.70M 1179.20M
Cost of revenue 1913.00M 2134.00M 1666.60M 1470.30M 1573.80M
Total other income expense net -424.00000M -864.00000M -773.50000M -264.40000M -170.10000M
Discontinued operations - - - - -
Net income from continuing ops -74.00000M -472.00000M -560.10000M 67.90M 86.50M
Net income applicable to common shares -78.00000M -472.00000M -560.10000M 67.90M 86.50M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 12614.00M 14362.00M 15491.00M 16483.00M 17692.70M
Intangible assets 3681.00M 4494.00M 4842.00M 5587.00M 6387.30M
Earning assets - - - - -
Other current assets 287.00M 310.00M 394.00M 237.00M 256.30M
Total liab 6518.00M 8139.00M 8202.00M 8945.00M 9216.80M
Total stockholder equity 6096.00M 6223.00M 7289.00M 7538.00M 8475.90M
Deferred long term liab - - - - -
Other current liab 975.00M 933.00M 924.00M 746.00M 872.20M
Common stock - - - - -
Capital stock 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Retained earnings -1950.00000M -2288.00000M -1057.00000M -949.00000M -477.20000M
Other liab - - 941.00M 1150.00M 1340.90M
Good will 4414.00M 5094.00M 5993.00M 6172.00M 6224.80M
Other assets - - 193.00M 183.00M 127.30M
Cash 468.00M 352.00M 345.00M 638.00M 494.70M
Cash and equivalents - - - - -
Total current liabilities 1315.00M 1241.00M 1702.00M 1643.00M 2076.30M
Current deferred revenue - 524.00M - 185.00M 148.60M
Net debt 3853.00M 5422.00M 5491.00M 5681.00M 5632.20M
Short term debt 44.00M 38.00M 388.00M 294.00M 554.50M
Short long term debt 44.00M 38.00M 388.00M 294.00M 554.50M
Short long term debt total 4321.00M 5774.00M 5836.00M 6319.00M 6126.90M
Other stockholder equity 8817.00M 8777.00M 8738.00M 8696.00M 8650.10M
Property plant equipment - - 999.00M 1222.00M 1316.30M
Total current assets 3215.00M 3407.00M 3279.00M 3276.00M 3416.50M
Long term investments - - - - -
Net tangible assets - - -3546.00000M -4325.00000M -4136.20000M
Short term investments - - - - -
Net receivables 886.00M 1010.00M 1002.00M 1028.00M 1076.70M
Long term debt 4277.00M 5736.00M 5448.00M 6025.00M 5572.40M
Inventory 1574.00M 1735.00M 1538.00M 1373.00M 1578.10M
Accounts payable 296.00M 270.00M 390.00M 418.00M 501.00M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -771.00000M -266.00000M -392.00000M -209.00000M 303.00M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - -1057.00000M -949.00000M -477.20000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 311.00M 315.00M 378.00M 387.00M 347.80M
Deferred long term asset charges - - - - -
Non current assets total 9399.00M 10955.00M 12212.00M 13207.00M 14276.20M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -179.00000M -530.00000M 32.70M -234.80000M -127.00000M
Change to liabilities -98.00000M -120.00000M 369.30M -29.20000M 116.10M
Total cashflows from investing activities -179.00000M -530.00000M -4779.20000M -234.80000M -127.00000M
Net borrowings -518.00000M 241.00M 3750.20M -121.10000M 2468.00M
Total cash from financing activities -549.00000M 210.00M 4953.90M -304.80000M -35.20000M
Change to operating activities -109.00000M 31.00M -122.90000M 7.00M -3.20000M
Net income -78.00000M -472.00000M -560.10000M 67.90M 86.50M
Change in cash -293.00000M 132.00M 160.30M -332.40000M 354.10M
Begin period cash flow 638.00M 506.00M 345.10M 677.50M 323.40M
End period cash flow 345.00M 638.00M 505.40M 345.10M 677.50M
Total cash from operating activities 452.00M 483.00M -41.00000M 224.10M 487.30M
Issuance of capital stock 0.00000M 0.00000M 1219.90M 0.00000M 1659.70M
Depreciation 682.00M 716.00M 516.90M 314.50M 296.00M
Other cashflows from investing activities -42.00000M -8.00000M -4677.30000M -94.40000M 7.50M
Dividends paid - - - - -
Change to inventory -269.00000M 27.00M -94.70000M -33.10000M -20.10000M
Change to account receivables 14.00M -3.00000M 14.00M -172.40000M -122.00000M
Sale purchase of stock - - 1219.90M - 1659.70M
Other cashflows from financing activities 941.00M 1033.00M 4685.50M -183.70000M -1687.40000M
Change to netincome 22.00M 326.00M -278.70000M 36.80M 13.50M
Capital expenditures 184.00M 197.00M 310.90M 197.40M 134.50M
Change receivables 14.00M -25.00000M 14.00M -172.40000M -122.00000M
Cash flows other operating 179.00M 434.00M -7.70000M 39.60M 117.30M
Exchange rate changes - - - - -
Cash and cash equivalents changes -276.00000M 163.00M 133.70M -315.50000M 325.10M
Change in working capital -462.00000M -87.00000M 165.70M -227.70000M -29.20000M
Stock based compensation 59.00M 66.00M 47.70M 49.40M 26.00M
Other non cash items 308.00M 414.00M -86.40000M 19.90M 168.70M
Free cash flow 268.00M 286.00M -351.90000M 26.70M 352.80M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ELAN
Elanco Animal Health		 -0.27 1.13% 23.67 17.23 15.20 1.45 1.01 2.33 7.36
ZTS
Zoetis Inc		 -1.87 1.53% 120.49 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.56 2.23% 25.64 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.64 2.02% 128.01 21.73 14.95 3.16 2.15 3.56 12.82
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.14 0.77% 18.21 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News

View All

Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. It offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio, Credelio Cat, Credelio Plus, Interceptor Plus, Doncit, Drontal, Drontal Plus, and Trifexis trademarks; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, it offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, the company offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and TruCan trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. It sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Elanco Animal Health

2500 Innovation Way, Greenfield, IN, United States, 46140

Key Executives

Name Title Year Born
Mr. Jeffrey N. Simmons Pres, CEO & Director 1967
Mr. Todd S. Young Exec. VP of Corp. Governance and Strategy & CFO 1972
Mr. Ramiro Martin Cabral Exec. VP & Pres of Elanco International 1972
Mr. James M. Meer Sr. VP & Chief Accounting Officer 1970
Mr. Chris Keeley Sr. VP & Chief Information Officer NA
Mr. David S. Kinard Exec. VP of HR Corp. Affairs & Admin. 1967
Ms. Marcela A. Kirberger Exec. VP, Gen. Counsel & Corp. Sec. 1967
Mr. David Alan Urbanek Exec. VP of Manufacturing & Quality 1967
Mr. Shawn McKee Sr. VP of U.S. Companion Animal NA
Mr. Larbi Van Lier Sr. VP of Asia NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.